Compare · GILD vs TCRX
GILD vs TCRX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and TScan Therapeutics Inc. (TCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TCRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $190.38B, about 14235.6x TCRX ($13.4M).
- Over the past year, GILD is up 32.2% and TCRX is down 90.5% - GILD leads by 122.7 points.
- GILD has been more active in the news (4 items in the past 4 weeks vs 3 for TCRX).
- GILD has more recent analyst coverage (25 ratings vs 10 for TCRX).
- Company
- Gilead Sciences Inc.
- TScan Therapeutics Inc.
- Price
- $155.80-1.03%
- $0.24-0.59%
- Market cap
- $190.38B
- $13.4M
- 1M return
- +3.16%
- -27.66%
- 1Y return
- +32.16%
- -90.51%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 10
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
TScan Therapeutics Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Latest GILD
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
Latest TCRX
- Chief Executive Officer Macbeath Gavin was granted 1,000,000 units of Voting Common Stock, increasing direct ownership by 2,009% to 1,049,767 units (SEC Form 4)
- Officer Zdraveski Zoran was granted 300,000 units of Voting Common Stock, increasing direct ownership by 6,361% to 304,716 units (SEC Form 4)
- SEC Form 8-K filed by TScan Therapeutics Inc.
- SEC Form 8-K filed by TScan Therapeutics Inc.
- TScan Therapeutics downgraded by H.C. Wainwright with a new price target
- TScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
- SEC Form 8-K filed by TScan Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.
- SEC Form 10-Q filed by TScan Therapeutics Inc.